Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinN (1)


SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 37
    records per page

    Clinical course and risk factors for in-hospital mortality of 205 patients with SARS-CoV-2 pneumonia MESHD in Como, Lombardy Region, Italy

    Authors: Mauro Turrini; Angelo Gardellini; Livia Beretta; Lucia Buzzi; Stefano Ferrario; Sabrina Vasile; Raffaella Clerici; Andrea Colzani; Luigi Liparulo; Giovanni Scognamiglio; Gianni Imperiali; Giovanni Corrado; Antonella Strada; Marco Galletti; Nunzio Castiglione; Claudio Zanon

    doi:10.1101/2021.02.25.20134866 Date: 2021-03-05 Source: medRxiv

    Importance: With randomized clinical trials ongoing and vaccine still a long distance away, efforts to repurpose old medications used for other diseases provide hope for treatment of COVID-19 MESHD. Objectives: To examine the risk factors for in-hospital mortality and describe the effectiveness of different treatment strategies in a real-life setting of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia MESHD. Design: Real-life single-center study during the Lombardy COVID-19 MESHD outbreak. Setting: Valduce Hospital in Como, Lombardy Region, Italy. Participants: 205 laboratory-confirmed patients presenting with SARS-Cov-2 pneumonia MESHD requiring hospitalization. Interventions: All patients received best supportive care and, based on their clinical needs and comorbidities, specific interventions that included the main drugs being tested for repurposing to treat COVID-19 MESHD, such as hydroxychloroquine, anticoagulation, antiviral drugs, steroids or interleukin-6 HGNC pathway inhibitors. Main outcomes and measures: Clinical, laboratory and treatment characteristics were analyzed with univariate and multivariate logistic regression methods to explore their impact on in-hospital mortality and compared with current literature data. Results: Univariate analyses for clinical variables showed prognostic significance for age equal or greater than 70 years (estimated 28-days survival: 21.4 vs 67.4%; p<0.0001), presence of 2 or more relevant comorbidities (35.3 vs 61.8%; p=0.0008), ratio of arterial oxygen partial pressure to fractional inspired oxygen (P/F) less than 200 at presentation (21-days survival: 14.7 vs 52.4%;p<0.0001), high levels of lactate dehydrogenase (LDH) (26.4 vs 65.3%; p=0.0001), and elevated C-reactive protein HGNC (CRP) values (25.4 vs 74.9%; p=0.0001), while no statistical significance was found for all the other clinical variables tested. At univariate analysis for the different treatment scheduled, prognostic significance for survival was showed for intermediate or therapeutic-dose anticoagulation (estimated 28-days survival: 37.1 vs 23.4%; p=0.0001), hydroxychloroquine (35.7 vs 27.3%; p=0.0029), early antiviral therapy with lopinavir/ritonavir (60.1 vs 22.4%; p<0.0001), late short-course of steroids (47.9 vs 18.2%; p<0.0001) or tocilizumab therapy (69.4 vs 29.4%; p=0.0059). Multivariable regression confirmed increasing odds of in-hospital death associated with age older than 70 years (odds ratio 3.26, 95% CI 1.81 - 5.86; p<0.0001) and showed a reduction in mortality for patients treated with anticoagulant (-0.37, 0.49 - 0.95; p=0.0273), antiviral (-1.22, 0.16 - 0.54; p<0.0001), or steroids (-0.59, 0.35 - 0.87; p=0.0117) therapy.

    Galectin-3 HGNC as a potential prognostic biomarker of severe COVID-19 MESHD in SARS-CoV-2 infected MESHD patients

    Authors: Eduardo Cervantes-Alvarez; Nathaly Limon-de la Rosa; Moises Salgado-de la Mora; Paola Valdez-Sandoval; Mildred Palacios-Jimenez; Fatima Rodriguez-Alvarez; Brenda I. Vera-Maldonado; Eduardo Aguirre-Aguilar; Juan Manuel Escobar-Valderrama; Jorge Alanis-Mendizabal; Osvely Mendez-Guerrero; Farid Tejeda-Dominguez; Jiram Torres-Ruiz; Diana Gomez-Martin; Kathryn L. Colborn; David Kershenobich; Christene A. Huang; Nalu Navarro-Alvarez

    doi:10.1101/2021.02.07.21251281 Date: 2021-02-09 Source: medRxiv

    BACKGROUNDPrognostic biomarkers are needed to identify patients at high-risk for severe COVID-19 MESHD. Galectin-3 HGNC is known to drive neutrophil infiltration and release of pro-inflammatory cytokines contributing to airway inflammation MESHD. METHODSIn this prospective cohort, we assessed galectin-3 HGNC levels in 156 hospitalized patients with confirmed COVID-19 MESHD. COVID-19 MESHD patients were diagnosed as either critical (>50% lung damage MESHD) or moderate (<50% of lung damage MESHD) based on computerized tomography. Patients who required invasive mechanical ventilation (IMV) and/or died during hospitalization were categorized as having a severe outcome, and a non-severe outcome if they were discharged and none of the former occurred. RESULTSElevated serum galectin-3 HGNC was significantly higher in critical patients compared to moderate ones (35.91 {+/-} 19.37 ng/mL vs. 25 {+/-} 14.85 ng/mL, p<0.0001). Patients who progressed to a severe outcome including IMV and/or in-hospital death, presented higher galectin-3 HGNC levels (41.17 ng/mL [IQR 29.71 - 52.25] vs. 23.76 ng/mL [IQR 15.78 - 33.97] compared to those of a non-severe outcome, p<0.0001). Galectin-3 HGNC discriminated well between those with severe and non-severe outcome, with an AUC of 0.75 (95% CI 0.67 - 0.84, p<0.0001) and was found to be an independent predictor of severe outcome regardless of the percentage of lung involvement. Additionally, the combination of galectin-3 HGNC, CRP HGNC and albumin, significantly improved its individual predicting ability with an AUC 0.84 (95% CI 0.77 - 0.91, p<0.0001). CONCLUSIONCirculating galectin-3 HGNC levels can be used to predict severe outcomes in COVID-19 MESHD patients, including the requirement of mechanical ventilation and/or death MESHD, regardless of the initial severity of the disease.


    Authors: Rodolfo Soria-Castro; Yatsiri G. Meneses-Preza; Gloria M. Rodriguez-Lopez; Sandra Romero-Ramirez; Victor A. Sosa-Hernandez; Rodrigo Cervantes-Diaz; Alfredo Perez-Fragoso; Jose J Torres-Ruiz; Diana Gomez-Martin; Marcia Campillo-Navarro; Violeta D. Alvarez-Jimenez; Sonia M. Perez-Tapia; Alma D. Chavez-Blanco; Sergio Estrada-Parra; Jose L. Maravillas-Montero; Rommel Chacon-Salinas

    doi:10.1101/2021.02.02.21251020 Date: 2021-02-03 Source: medRxiv

    The immune response plays a critical role in the pathophysiology of SARS-CoV-2 infection MESHD ranging from protection to tissue damage. This is observed in the development of acute respiratory distress syndrome MESHD when elevated levels of inflammatory cytokines are detected. Several cells of the immune response are implied in this dysregulated immune response including innate immune cells and T and B cell lymphocytes. Mast cells are abundant resident cells of the respiratory tract, able to rapidly release different inflammatory mediators following stimulation. Recently, mast cells have been associated with tissue damage during viral infections, but little is known about their role in SARS-CoV-2 infection MESHD. In this study we examined the profile of mast cell activation markers in the serum of COVID-19 MESHD patients. We noticed that SARS-CoV-2 infected MESHD patients showed increased carboxypeptidase A3 HGNC ( CPA3 HGNC), and decreased serotonin levels in their serum. CPA3 HGNC levels correlated with C-reactive protein HGNC, the number of circulating neutrophils and quick SOFA. CPA3 HGNC in serum was a good biomarker for identifying severe COVID-19 MESHD patients, while serotonin was a good predictor of SARS-CoV-2 infection MESHD. In summary, our results show that serum CPA3 HGNC and serotonin levels are relevant biomarkers during SARS-CoV-2 infection MESHD, suggesting that mast cells are relevant players in the inflammatory response in COVID-19 MESHD, might represent targets for therapeutic intervention.

    COVID-19 MESHD anosmia MESHD and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 MESHD (Health Outcome Predictive Evaluation for COVID-19 MESHD) Registry

    Authors: Jesús Porta-Etessam; Iván Núñez-Gil; Nuria González García; Cristina Fernández; María Viana-LLamas; Charbel Maroun Eid; Rodolfo Romero; Marta Molina; Aitor Uribarri; Victor Becerra; Marcos García Aguado; Jia Huang; Elisa Rondano; Enrico Cerrato; Emilio Alfonso; Alex Castro; francisco Marín; Sergio Raposeiras; Martino Pepe; Gisela Feites; Paloma Mate; Bernardo Cortese; Luís Buzón; Jorge Javita; Vicente Estrada

    doi:10.21203/ Date: 2021-01-27 Source: ResearchSquare

    Olfactory and gustatory dysfunctions MESHD ( OGD MESHD) are a frequent symptom of Coronavirus disease 2019 MESHD ( COVID-19 MESHD). It has been proposed that the neuroinvasive potential of the novel SARS-CoV-2 could be due to olfactory bulb invasion, conversely studies suggest it could be a good prognostic factor. The aim of the current study was to investigate the prognosis value of OGD in COVID-19 MESHD.These symptoms were recorded on admission from a cohort study of 5868 patients with confirmed or highly suspected COVID-19 MESHD infection included in the multicenter international HOPE Registry (NCT04334291).There was statistical relation in multivariate analysis for OGD in gender, more frequent in female 12.41% vs 8.67% in male, related to age, more frequent under 65 years, presence of hypertension MESHD, dyslipidemia MESHD, diabetes MESHD, smoke, renal insufficiency MESHD, lung, heart, cancer MESHD and neurological disease MESHD. We did not find statistical differences in pregnant (p=0.505), patient suffering cognitive (p=0.484), liver (p=0.1) or immune disease (p=0.32). There was inverse relation (protective) between OGD MESHD and prone positioning (0.005) and death MESHD (<0.0001), but no with ICU (0.165) or mechanical ventilation (0.292). On univariable logistic regression OGD was found to be inversely related to death in COVID-19 MESHD patients. The Odds Ratio was 0.26 (0.15-0.44) (p<0.001) and Z was -5.05.The presence of anosmia MESHD is fundamental in the diagnosis of SARS.CoV-2 infection MESHD, but also could be important when classifying patients and in therapeutic decisions. Even more knowing that it is an early symptom of the disease. Knowing that other situations as being Afro-American or Latino-American, Hypertension MESHD, renal insufficiency MESHD, or increase of C-reactive protein HGNC ( CRP HGNC) imply a worse prognosis we can make a clinical score to estimate the vital prognosis of the patient.The exact pathogenesis of SARS-CoV-2 that causes olfactory and gustative disorders remains unknown but seems related to the prognosis. This point is fundamental, insomuch as could be a plausible way to find a treatment. 

    Cerebrospinal fluid in COVID-19 MESHD neurological complications: no cytokine storm or neuroinflammation.

    Authors: Maria A. Garcia; Paula V. Barreras; Allie Lewis; Gabriel Pinilla; Lori J. Sokoll; Thomas Kickler; Heba Mostafa; Mario Caturegli; Abhay Moghekar; Kathryn C. Fitzgerald; - Hopkins Neuro-COVID-19 Group; Carlos A Pardo

    doi:10.1101/2021.01.10.20249014 Date: 2021-01-12 Source: medRxiv

    BACKGROUND. Neurological complications MESHD occur in COVID-19 MESHD. We aimed to examine cerebrospinal fluid (CSF) of COVID-19 MESHD subjects with neurological complications MESHD and determine presence of neuroinflammatory changes implicated in pathogenesis. METHODS. Cross-sectional study of CSF neuroinflammatory profiles from 18 COVID-19 MESHD subjects with neurological complications categorized by diagnosis ( stroke MESHD, encephalopathy MESHD, headache MESHD) and illness severity (critical, severe, moderate, mild). COVID-19 MESHD CSF was compared with CSF from healthy, infectious and neuroinflammatory disorders MESHD and stroke MESHD controls (n=82). Cytokines ( IL-6 HGNC, TNF-alpha HGNC, IFN-gamma HGNC, IL-10 HGNC, IL-12p70, IL-17A HGNC), inflammation MESHD and coagulation markers (high-sensitivity- C Reactive Protein HGNC [hsCRP], ferritin, fibrinogen HGNC, D-dimer, Factor VIII) and neurofilament light chain ( NF-L HGNC), were quantified. SARS-CoV2 RNA and SARS-CoV2 IgG and IgA antibodies in CSF were tested with RT-PCR and ELISA. RESULTS. CSF from COVID-19 MESHD subjects showed a paucity of neuroinflammatory changes, absence of pleocytosis MESHD or specific increases in pro-inflammatory markers or cytokines ( IL-6 HGNC, ferritin, or D-dimer). Anti-SARS-CoV2 antibodies in CSF of COVID-19 MESHD subjects (77%) were observed despite no evidence of SARS-CoV2 viral RNA. A similar increase of pro-inflammatory cytokines ( IL-6 HGNC, TNF-alpha HGNC;, IL-12p70) and IL-10 HGNC in CSF of COVID-19 MESHD and non- COVID-19 MESHD stroke MESHD subjects was observed compared to controls. CSF-NF-L was elevated in subjects with stroke MESHD and critical COVID-19 MESHD. CSF-hsCRP was present almost exclusively in COVID-19 MESHD cases. CONCLUSION. The paucity of neuroinflammatory changes in CSF of COVID-19 MESHD subjects and lack of SARS-CoV2 RNA do not support the presumed neurovirulence of SARS-CoV2 or neuroinflammation MESHD in pathogenesis of neurological complications in COVID-19 MESHD. Elevated CSF-NF-L indicates neuroaxonal injury MESHD in COVID-19 MESHD cases. The role of CSF SARS-CoV2 IgG antibodies is still undetermined.

    The kidnapping of mitochondrial function associated to the SARS-CoV-2 infection MESHD

    Authors: Elizabeth Soria-Castro; María Elena Soto; Verónica; Gustavo Rojas; Mario Perezpeña-Diazconti; Sergio A Críales-Vera; Linaloe Manzano Pech; Israel Pérez-Torres

    doi:10.21203/ Date: 2020-12-29 Source: ResearchSquare

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection leads to multiorganic failure MESHD associated with a cytokine storm and septic shock MESHD. The virus evades the mitochondrial production of interferons through its N protein PROTEIN. From that moment on, SARS-CoV-2 hijacks MESHD the functions of this organelle. The aim of this study was to show how the virus kidnaps the mitochondrial machinery for its benefit and survival, altering serum parameters and leading to nitrosative stress (NSS). In a prospective cohort of 15 postmortem patients who died from COVID-19 MESHD, six markers of mitochondrial function; COX II, COX IV HGNC, MnSOD HGNC, nitrotyrosine, Bcl-2 HGNC and caspase-9 HGNC were analyzed by the immune colloidal gold technique in samples from the lung, heart, kidney and liver. Biometric laboratory results from these patients showed alterations in hemoglobin, platelets, creatinine, urea nitrogen, glucose, C-reactive protein HGNC, albumin, D-dimer, ferritin, fibrinogen HGNC, Ca2+, K+, lactate and troponin. These changes were associated with alterations of the mitochondrial structure and function. The multiorganic dysfunction MESHD present in COVID-19 MESHD patients may be caused in part by damage to the mitochondria that results in an inflammatory state that contributes to the elevation of NSS. NSS activates the sepsis MESHD cascade and contributes to the increased mortality in COVID-19 MESHD patients.

    Dutasteride Reduces Viral Shedding, Inflammatory Responses and Time-to-Remission in COVID-19 MESHD: Biochemical Findings of a Randomized Double-Blind Placebo Controlled Interventional Trial (DUTA AndroCoV-Trial - Biochemical). 

    Authors: Flávio Adsuara Cadegiani; John McCoy; Carlos Gustavo Wambier; Andy Goren

    doi:10.21203/ Date: 2020-12-24 Source: ResearchSquare

    Importance: SARS-CoV-2 cell entry and infectivity is indirectly dependent on androgenic status and phenotype through the regulation of t ransmembrane protease serine 2 HGNC(T MPRSS2) HGNC, an androgen-mediated proteolytic enzyme that facilitates SARS-CoV-2 entry.  Males, particularly those affected by androgenetic alopecia (AGA) are overrepresented in severe COVID-19 MESHD, while the use of 5-alpha-reductase inhibitors (5ARis), an antiandrogenic drug class, may reduce COVID-19 MESHD severity. Objective: Our objective was to determine if dutasteride, a wide and potent 5ARi, would bring biochemical and virological benefits in early COVID-19 MESHD.Design, Setting, and Participants: A double-blinded, randomized, prospective, investigational study of dutasteride for the treatment of COVID-19 MESHD, as add-on therapy to the local standard of care, for mild or moderate, non-hospitalized subjects confirmed for S ARS-CoV-2 MESHD(The Duta AndroCoV Trial).Interventions:  Dutasteride 0.5mg/day or placebo for 30 days or until full COVID-19 MESHD remission. Nitazoxanide was given 500mg twice a day for six days and azithromycin was given 500mg/day for five days for all subjects.Main Outcome(s) and Measure(s): Remission times for fatigue, ageusia, anosmia, and overall disease, oxygen saturation (%), real-time polymerase chain reaction (rtPCR-SARS-CoV-2), ultrasensitive C -reactive protein HGNC(usCRP), D-dimer, lactate, dehydrogenase lactate (DHL), erythrocyte sedimentation rate (ESR), ultrasensitive troponin and ferritin.Results:  Compared to placebo group (n=44) with similar baseline characteristics, dutasteride (n=43) presented reduced fatigue, anosmia and overall disease duration (46.6%, 49.6% and 43.2% lower duration, respectively; p<.0001 for all), and in Day 7 presented higher rates of virologic cure (64.3% versus 11.8% cure; p=.0094), , increased recovery rate (84.7% versus 57.5%; p=.03), higher mean [SD] oxygen saturation (97.0% [1.4%] versus 95.7% [2.0%]; p=.02), lower median [IQR] usCRP (0.34mg/L [0.23mg/L -0.66mg/L] versus 1.47mg/L [0.70mg/L-3.37mg/L]; p<.0001),  lower median [IQR] lactate (2.01mmol/L [1.12mmol/L-2.43mmol/L] versus 2.66mmol/L [2.05mmol/L-3.55mmol/L]; p=.0049), lower median [IQR] ESR (5.0mm/1h [3.0mm/1h-11.0mm/1h] versus 14.0mm/1h [7.25mm/1h-18.5mm/1h]; p=.0007), lower median [IQR] LDH (165U/L [144U/L -198U/L] versus 210U/L [179U/L-249U/L]; p=.0013 and lower median [IQR] troponin levels (0.005ng/mL [0.003ng/mL-0.009ng/mL] versus 0.007ng/mL [0.006ng/mL-0.010ng/mL]; p=.048).Conclusions and Relevance: These findings suggest that dutasteride reduces clinical and virologic disease duration and inflammatory markers in males with mild-to-moderate, early-stage COVID-19 MESHD, and should be considered as a therapeutic option in the current context of the COVID-19 pandemic MESHD.Trial Registration: NCT04446429

    Evaluation of symptoms, radiological findings, laboratory data and outcome in COVID-19 MESHD patients with chronic kidney disease at Tehran, Iran

    Authors: Yasaman Sadat Keshmiri; Sina Khosravi Mirzaie; Shahnaz Sali; Davood Yadegarynia; Sara Abolghasemi; Shabnam Tehrani; Amir Zamani; Mohamad Mehdi Derisi

    doi:10.21203/ Date: 2020-10-31 Source: ResearchSquare

    Background: Chronic kidney disease MESHD ( CKD MESHD) patients are a large population and of significant importance. Except for having an underlying disease, they have some other risk factors, for example, old age, impaired immune function, and other comorbidities that make them more susceptible to the new SARS-COV2 infection MESHD.Methods: As data on CKD MESHD patients with SARS-CoV-2 Infection MESHD is limited, we decided to carry out a cross-sectional study at Labbafinezhad Hospital on 78 CKD MESHD patients with approved COVID-19 MESHD infection either on dialysis or not. We have also incorporated CKD MESHD patients with kidney transplant history. Results: The mean age of the patients was 64.04 years, including 53 women and 25 men. Among all symptoms, dyspnea MESHD (19.2%) was the most prevalent one. Laboratory data analysis shows an increase in LDH, Creatinine, and ESR and CRP HGNC levels. The most common finding on chest CT-Scan was bilateral ground-glass opacity detected in 31 (86.1%) patients, followed by pleural effusion MESHD (12.8%) and atelectasis (19%). Among included patients, 53 (74.6%) had hypoxia MESHD (o2 saturation 94% and lower), 47 (81%) had tachypnea MESHD (respiratory rate over 16) and 9 (23.1%) had some reduction in the level of consciousness (GCS lower than 15). Conclusion: Due to the important effect of underlying medical conditions on the outcome of COVID-19 MESHD patients, evaluation of clinical manifestations, radiologic findings, laboratory data, and outcome of COVID-19 MESHD patients with chronic kidney disease MESHD is important to establish a perspective for physicians to manage CKD MESHD patients.

    Clinical course of COVID-19 MESHD patients needing supplemental oxygen outside the intensive care unit

    Authors: Ayham Daher; Paul Balfanz; Maria Aetou; Bojan Hartmann; Dirk Müller-Wieland; Tobias Müller; Nikolaus Marx; Michael Dreher; Christian G Cornelissen

    doi:10.21203/ Date: 2020-10-20 Source: ResearchSquare

    Purpose: Patients suffering from CVOID-19 mostly experience a benign course of the disease. Approximately 14 % of SARS-CoV2 infected MESHD patients are admitted to a hospital. Cohorts exhibiting severe lung failure MESHD in the form of acute respiratory distress syndrome MESHD ( ARDS MESHD) have been well characterized. Patients without ARDS MESHD but in need of supplementary oxygen have received much less attention. This study describes the diagnosis, symptoms, treatment and outcomes of hospitalized patients with COVID-19 MESHD needing oxygen support during their stay on regular ward.Methods: All 133 patients admitted to the RWTH Aachen university hospital with the diagnosis of COVID-19 MESHD were included in an observational registry. Clinical data sets were extracted from the hospital information system. This analysis includes all 57 patients requiring supplemental oxygen not admitted to the ICU.Results: 57 patients needing supplemental oxygen and being treated outside the ICU were analyzed. Patients exhibited the typical set of symptoms for COVID-19 MESHD. Of note, hypoxic MESHD patients mostly did not suffer from clinically relevant dyspnea MESHD despite oxygen saturations below 92 %. Patients had fever MESHD for 7 [2-11] days and needed supplemental oxygen for 8 [5-13] days resulting in an overall hospitalization time of 12 [7-20] days. In addition, patients had persisting systemic inflammation MESHD with CRP HGNC levels remaining elevated until discharge or death MESHD.Conclusion: This description of COVID-19 MESHD patients requiring oxygen therapy should be taken into account when planning treatment capacity. Patients on oxygen need long-term inpatient care.

    The COVID-19 MESHD Lab Score: An Accurate Dynamic Tool to Predict In-Hospital Outcomes in COVID-19 MESHD Patients

    Authors: Pablo J. Antunez Muiños; Diego López Otero; Ignacio J. Amat-Santos; Javier López Pais; Alvaro Aparisi; Carla E. Cacho Antonio; Pablo Catalá; Teba González Ferrero; Gonzalo Cabezón; Oscar Otero García; José Francisco Gil; Marta Pérez Poza; Jordi Candela; Gino Rojas; Víctor Jiménez Ramos; Carlos Veras; J. Alberto San Román; José R. González-Juanatey

    doi:10.21203/ Date: 2020-10-12 Source: ResearchSquare

    Purpose: Deterioration is sometimes unexpected in SARS-CoV2 infection MESHD. The aim of our study is to establish laboratory predictors of mortality in COVID-19 MESHD disease which can help to identify high risk patients.Methods: All patients admitted to hospital due to Covid-19 MESHD disease were included. Laboratory biomarkers that contributed with significant predictive value for predicting mortality to the clinical model were included. Cut-off points were established, and finally a risk score was built. Results: 893 patients were included. Median age was 68.2 years(CI 95% 53.0-83.4). 87(9.7%) were admitted to Intensive Care Unit(ICU) and 72(8.1%) also needed mechanical ventilation support. 171(19.1%) patients died. A Covid-19 MESHD Lab score ranging from 0 to 30 points was calculated on the basis of a multivariate logistic regression model in order to predict mortality with a weighted score that included haemoglobin, erythrocytes, leukocytes, neutrophils, lymphocytes, creatinine, C-reactive protein HGNC, interleukin-6 HGNC, procalcitonin, lactate dehydrogenase (LDH), and D-dimer. Three groups were established. Low mortality risk group under 12 points, 12 to 18 were included as moderate risk, and high risk group were those with 19 or more points. Low risk group as reference, moderate and high patients showed mortality OR 4.75(CI95% 2.60-8.68) and 23.86(CI 95% 13.61-41.84), respectively. C-statistic was 0-85(0.82-0.88) and Hosmer-Lemeshow p-value 0.63.Conclusion: Covid-19 MESHD Lab score can very easily predict mortality in patients at any moment during admission secondary to SARS-CoV2 infection MESHD. It is a simple and dynamic score, and it can be very easily replicated. It could help physicians to identify high risk patients to foresee clinical deterioration.  

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.